CLINICAL TRIALS PROFILE FOR LOVENOX

All Clinical Trials for LOVENOX

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00289042 ↗	Assessment of Cardioversion Using Transesophageal Echocardiography II (ACUTE II)	Completed	Sanofi	Phase 4	1999-12-01	SPECIFIC AIM: To test the safety and feasibility of using low molecular weight heparin (LMWH, enoxaparin sodium; Lovenox, Sanofi-Aventis) in lieu of unfractionated heparin (UFH) as antithrombotic therapy for patients in atrial fibrillation undergoing transesophageal echocardiography (TEE) guided chemical or electrical cardioversion to sinus rhythm. HYPOTHESIS: Early cardioversion from atrial fibrillation can be safely performed using a short-term anticoagulation strategy of low molecular weight heparin (Lovenox, Sanofi-Aventis) compared to unfractionated heparin, accompanied by a TEE examination prior to cardioversion. The use of LMWH with TEE will result in a safe, cost-effective, and possible efficacious approach to cardioversion of atrial fibrillation compared to UFH with TEE.
NCT00289042 ↗	Assessment of Cardioversion Using Transesophageal Echocardiography II (ACUTE II)	Completed	The Cleveland Clinic	Phase 4	1999-12-01	SPECIFIC AIM: To test the safety and feasibility of using low molecular weight heparin (LMWH, enoxaparin sodium; Lovenox, Sanofi-Aventis) in lieu of unfractionated heparin (UFH) as antithrombotic therapy for patients in atrial fibrillation undergoing transesophageal echocardiography (TEE) guided chemical or electrical cardioversion to sinus rhythm. HYPOTHESIS: Early cardioversion from atrial fibrillation can be safely performed using a short-term anticoagulation strategy of low molecular weight heparin (Lovenox, Sanofi-Aventis) compared to unfractionated heparin, accompanied by a TEE examination prior to cardioversion. The use of LMWH with TEE will result in a safe, cost-effective, and possible efficacious approach to cardioversion of atrial fibrillation compared to UFH with TEE.
NCT00358735 ↗	Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)	Completed	Medical Compression Systems	N/A	2006-06-01	Evaluation of the safety and effectiveness of ActiveCare+ CECT device +/- baby dose aspirin (81 mg QD) for lowering the potential risk for bleeding and of DVT during and after THA surgery in comparison with LMWH.
NCT00371683 ↗	Study of Apixaban for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery	Completed	Bristol-Myers Squibb	Phase 3	2006-11-01	The purpose of this study is to learn if apixaban can prevent blood clots in the leg (deep vein Thrombosis [DVT]) and lung (pulmonary embolism [PE]) that sometimes occur after knee replacement surgery and to learn how apixaban compares to enoxaparin (Lovenox®) for preventing these clots. The safety of apixaban will also be studied.
NCT00375609 ↗	Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)	Completed	Portola Pharmaceuticals	Phase 2	2006-05-01	Randomized study of PRT054021 40 mg and 15 mg bid vs. enoxaparin 30 mg q12h for the prophylaxis of venous thromboembolic events after unilateral knee replacement surgery.
NCT00413374 ↗	Once Daily Enoxaparin for Outpatient Treatment of Acute DVT and/or Pulmonary Embolism	Completed	Sanofi	N/A	2006-05-01	To investigate the efficacy and safety of once daily enoxaparin as a "bridge" to warfarin for the outpatient treatment of acute deep venous thrombosis or pulmonary embolism.
NCT00413374 ↗	Once Daily Enoxaparin for Outpatient Treatment of Acute DVT and/or Pulmonary Embolism	Completed	Brigham and Women's Hospital	N/A	2006-05-01	To investigate the efficacy and safety of once daily enoxaparin as a "bridge" to warfarin for the outpatient treatment of acute deep venous thrombosis or pulmonary embolism.

Clinical Trial Conditions for LOVENOX

Condition Name

Condition Name for LOVENOX
Intervention	Trials
Venous Thromboembolism	13
Pulmonary Embolism	10
Deep Vein Thrombosis	7
Venous Thrombosis	6

Condition MeSH

Condition MeSH for LOVENOX
Intervention	Trials
Thrombosis	24
Venous Thrombosis	23
Thromboembolism	20
Venous Thromboembolism	15

Clinical Trial Locations for LOVENOX

Trials by Country

Trials by Country for LOVENOX
Location	Trials
United States	140
Mexico	16
India	15
Canada	12
Brazil	12

Trials by US State

Trials by US State for LOVENOX
Location	Trials
California	10
New York	9
Texas	8
Massachusetts	7
Ohio	6

Clinical Trial Progress for LOVENOX

Clinical Trial Phase

Clinical Trial Phase for LOVENOX
Clinical Trial Phase	Trials
Phase 4	19
Phase 3	8
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for LOVENOX
Clinical Trial Phase	Trials
Completed	35
Terminated	12
Recruiting	9

Clinical Trial Sponsors for LOVENOX

Sponsor Name

Sponsor Name for LOVENOX
Sponsor	Trials
Sanofi	6
Bristol-Myers Squibb	4
GlaxoSmithKline	4

Sponsor Type

Sponsor Type for LOVENOX
Sponsor	Trials
Other	96
Industry	27
U.S. Fed	8